Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ottignies – page 68

1 888 clinical trials in Ottignies, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ottignies at a glance
1 888
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 888 trials in Ottignies

Open in trial search

Loss of consciousness

Not yet recruiting

Study on Zolpidem's Effects in Patients with Vision Impairments, Disorders of Consciousness, and Neurotypical Volunteers

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Mannitol
  • Sponsor:Universite De Liege

COVID-19

Not yet recruiting

Study on COVID-19 Immunity in Immunocompromised Adults Using Raxtozinameran and Bretovameran in Belgium

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Bretovameran
  • Sponsor:Sciensano

Autism spectrum disorder

Not yet recruiting

Study on Improving Social Interaction in Children with Autism Using Oxytocin Nasal Spray and Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:Oxytocin
  • Sponsor:UZ Leuven

Arteriovenous malformation

Not yet recruiting

Study on the Safety and Effectiveness of Regorafenib for Patients with Arterio-Venous Malformations Unresponsive to Standard Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Regorafenib
  • Sponsor:Cliniques Universitaires Saint-Luc

HIV infection

Not yet recruiting

Study on the Safety and Immune Response of the 9-Valent HPV Vaccine in Women Living with HIV

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
  • Sponsor:CHU Saint Pierre

Cholangitis sclerosing

Not yet recruiting

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Study on Alkaline Phosphatase to Prevent Inflammation and Kidney Injury in Patients Undergoing Open-Heart Surgery

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alkaline Phosphatase, Bovine
  • Sponsor:Alloksys Life Sciences B.V.

Breast cancer+2

Not yet recruiting

A study of Zr89-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab
  • Sponsor:Institut Jules Bordet

Glioblastoma

Not yet recruiting

Study on Glioblastoma Treatment with Temozolomide, Lomustine, and Perflutren for Newly Diagnosed Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:Assistance Publique Hopitaux De Paris

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of Lutikizumab and Adalimumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cardiac sarcoidosis

Not yet recruiting

Detecting Heart Inflammation in Cardiac Sarcoidosis Patients Using 68Ga-NOTA-Anti-MMR-VHH2 PET-CT Imaging

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:68GaNOTA-anti-MMR-VHH2
  • Sponsor:Cliniques Universitaires Saint-Luc

Brain injury+1

Not yet recruiting

Study on Ketamine for Treating Patients with Severe Brain Injury and Disorders of Consciousness

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ketamine
  • Sponsor:CHU De Liege

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ottignies

What the registry says about research in the country

01 Neurology and Consciousness Disorders

Clinical research in Ottignies includes studies focused on nervous system diseases and the recovery of patients with disorders of consciousness after severe brain injury or coma. These trials are exploring whether targeted therapies can improve wakefulness, responsiveness, and overall neurological recovery.

  • Evaluation of ketamine for post-comatose patients with impaired consciousness
  • Assessment of apomorphine hydrochloride for severe brain injury and consciousness recovery
  • Study of zolpidem responses in patients with disorders of consciousness
  • Research into the mechanisms behind paradoxical neurological responses

Together, these trials aim to improve treatment options and deepen understanding of how the brain may respond to therapy in complex neurological conditions.

02 Respiratory Infections and Critical Care

Another active area of research covers respiratory tract diseases, especially severe community-acquired pneumonia and broader respiratory tract infection care in hospitalized patients. The goal is to identify better ways to support recovery and reduce serious outcomes in people admitted with acute infections.

  • Testing supportive interventions for hospitalized patients with acute respiratory tract infection
  • Evaluating treatment options for severe community-acquired pneumonia
  • Measuring effects on survival and recovery over time

This line of research is particularly relevant for intensive care settings, where timely and effective treatment can strongly influence patient outcomes.

03 Oncology and Breast Cancer

In the field of neoplasms, trials are studying advanced breast cancer with specific genetic features, including ER-positive and HER2-negative disease. Research is centered on whether new treatment combinations can improve disease control in patients with hard-to-treat cancers.

  • Testing a combination approach for selected metastatic breast cancer patients
  • Focusing on tumors with BRCA and HRR alterations
  • Assessing benefits in patients with advanced hormone-receptor-positive disease

These studies are designed to evaluate treatment effectiveness and offer more personalized options for people with genetically defined cancer subtypes.

04 Epilepsy and Rare Neurological Syndromes

Research in nervous system diseases also includes long-term treatment studies for rare epileptic disorders such as Dravet syndrome and Lennox-Gastaut syndrome. The emphasis is on improving seizure control while keeping therapy safe and tolerable over time.

  • Long-term safety evaluation of soticlestat as add-on therapy
  • Support for patients already receiving standard epilepsy care
  • Focus on chronic management of Dravet syndrome and Lennox-Gastaut syndrome

This research is important for families and clinicians seeking better options for rare and severe seizure disorders.

05 Women’s Health and Viral Infections

Within female urogenital diseases and pregnancy-related conditions, clinical trials are examining human papillomavirus infection and strategies to help clear persistent genital HPV. The main purpose is to test whether new approaches can improve infection outcomes and reduce long-term risk.

  • Comparing a candidate intervention with placebo for genital HPV clearance
  • Targeting high-risk oncogenic HPV infections
  • Supporting prevention efforts in women’s health

This area links infection control with cancer prevention, making it a meaningful focus in preventive medicine.

06 Vision Research and Physiological Responses

A smaller but distinctive research stream examines physiological processes in people with acquired partial or total vision impairments and in neurotypical volunteers. These studies aim to better understand unusual responses to treatment and how such responses may inform personalized care.

  • Studying temporary visual improvement in patients with vision impairments
  • Comparing responses in volunteers and patient groups
  • Exploring how unusual drug responses may reveal biological mechanisms

The findings may help clarify why some individuals respond differently to the same treatment and support more tailored clinical decisions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.